微信内可能无法直接打开本站。请点右上角 ··· → 在浏览器打开，或复制链接。
STAT+: Alnylam defends heart disease drugs after failure of AstraZeneca’s Wainua
RSS 官方收录 · 可信分层展示
关键摘要
Alnylam力挺RNAi药物，回应阿斯利康Wainua心衰试验失败影响
- 阿斯利康Wainua治疗ATTR-CM心衰三期试验失败
- 部分分析师质疑RNAi沉默剂在联用稳定剂时无额外获益
- Alnylam为已上市药Amvuttra及在研药nucresiran辩护
AI 摘要 · 来源可核验
正文提要
When AstraZeneca on Friday detailed the failed trial of its drug Wainua in a heart condition known as ATTR-CM, the bad news, according to one school of thought, extended to Alnylam Pharmaceuticals.
Some analysts interpreted the study’s miss as a broad sign that silencers — the kind of medicine that Alnylam sells and that AstraZeneca was testing — offered no added benefits if patients were already on another kind of drug known as a stabilizer, and as an indication that stabilizers might be superior.
Now, Alnylam is mounting a defense of its silencers, with ramifications both for its marketed drug Amvuttra, and for its next-gen treatment nucresiran.